JP2017525343A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525343A5
JP2017525343A5 JP2017501280A JP2017501280A JP2017525343A5 JP 2017525343 A5 JP2017525343 A5 JP 2017525343A5 JP 2017501280 A JP2017501280 A JP 2017501280A JP 2017501280 A JP2017501280 A JP 2017501280A JP 2017525343 A5 JP2017525343 A5 JP 2017525343A5
Authority
JP
Japan
Prior art keywords
hil
antigen
binding
nmol
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017501280A
Other languages
English (en)
Japanese (ja)
Other versions
JP7209464B2 (ja
JP2017525343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/055226 external-priority patent/WO2016005950A1/en
Publication of JP2017525343A publication Critical patent/JP2017525343A/ja
Publication of JP2017525343A5 publication Critical patent/JP2017525343A5/ja
Application granted granted Critical
Publication of JP7209464B2 publication Critical patent/JP7209464B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017501280A 2014-07-10 2015-07-10 ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 Active JP7209464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176619.6 2014-07-10
EP14176619 2014-07-10
PCT/IB2015/055226 WO2016005950A1 (en) 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2

Publications (3)

Publication Number Publication Date
JP2017525343A JP2017525343A (ja) 2017-09-07
JP2017525343A5 true JP2017525343A5 (enExample) 2018-08-16
JP7209464B2 JP7209464B2 (ja) 2023-01-20

Family

ID=51162588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501280A Active JP7209464B2 (ja) 2014-07-10 2015-07-10 ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体

Country Status (9)

Country Link
US (2) US10894828B2 (enExample)
EP (2) EP3166973B1 (enExample)
JP (1) JP7209464B2 (enExample)
CN (1) CN106604932B (enExample)
AU (1) AU2015287227B2 (enExample)
CA (1) CA2954476C (enExample)
DK (1) DK3166973T3 (enExample)
ES (2) ES2989669T3 (enExample)
WO (1) WO2016005950A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43859A (fr) * 2016-01-11 2018-11-21 Novartis Ag Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
KR20190057113A (ko) 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CN110913873A (zh) * 2017-02-23 2020-03-24 希望之城 用于cd8+t细胞的体内扩增并预防或治疗gvhd的方法
BR112019019595A2 (pt) * 2017-03-23 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
BR112019024745B1 (pt) * 2017-05-25 2024-01-16 Institute For Basic Science Anticorpo anti-hil-2 ou fragmento de ligação a antígeno do mesmo,ácido nucleico, vetor recombinante, célula procariótica transformada, método para a produção de um anticorpo anti-hil-2 ou um fragmento do mesmo e complexo
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4090377A1 (en) 2020-01-13 2022-11-23 Synaffix B.V. Conjugates of antibodies an immune cell engagers
CN115397852B (zh) 2020-02-16 2023-08-11 奥罗斯生物科学公司 工程化抗il-2抗体
US20230303680A1 (en) * 2020-08-18 2023-09-28 Universität Zürich A cd25-biased anti-il-2 antibody
EP4288108A1 (en) 2021-02-08 2023-12-13 Synaffix B.V. Multifunctional antibodies
KR20240082411A (ko) 2021-10-14 2024-06-10 라띠콘 (수저우) 바이오파마슈티칼스 코., 엘티디. 신규 항체-사이토카인 융합 단백질, 이의 제조 방법 및 이의 용도
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119912559A (zh) * 2025-01-22 2025-05-02 贵州中医药大学 一种新冠病毒变异株jn.1刺突s蛋白的单链抗体及其应用
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174501B1 (da) * 1983-12-23 2003-04-28 Hoffmann La Roche Fremgangsmåde til fremstilling af interleukin-2
DK134487A (da) * 1986-03-17 1987-09-18 Hoffmann La Roche Monoklonalt antistof med affinitet for humant interleukin-2
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
JP4440344B2 (ja) 1996-08-16 2010-03-24 シェーリング コーポレイション 哺乳動物細胞表面抗原；関連試薬
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
EP1578419A4 (en) 2002-12-30 2008-11-12 3M Innovative Properties Co IMMUNOSTIMULATING COMBINATIONS
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
WO2006128690A1 (en) * 2005-06-01 2006-12-07 Micromet Ag Anti-il2 antibodies
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
EP1987065A4 (en) * 2006-02-16 2010-01-20 Nascent Biolog Inc METHOD FOR IMPROVING THE IMMUNE FUNCTION AND METHOD FOR PREVENTING OR TREATING DISEASES IN MAMMALS
CN101045923B (zh) * 2006-03-31 2011-11-23 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
CA2715166C (en) 2008-02-11 2017-05-16 Curetech Ltd. Monoclonal antibodies for tumor treatment
BR112013004056B8 (pt) * 2010-08-12 2022-10-18 Lilly Co Eli Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
ES2579987T3 (es) 2011-02-10 2016-08-18 Roche Glycart Ag Polipéptidos interleuquina-2 mutantes
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2017525343A5 (enExample)
JP2022177090A5 (enExample)
JP2018536393A5 (enExample)
PE20210342A1 (es) Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2020500538A5 (enExample)
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
MY198942A (en) Anti-tau antibodies and methods of use
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
JP2017505125A5 (enExample)
JP2019528683A5 (enExample)
RU2014108309A (ru) Антиполиубиквитиновые антитела и способы применения
JP2020537520A5 (enExample)
PE20240802A1 (es) Anticuerpos multiespecificos con especificidad para il-4r e il-31
NZ628943A (en) Human antibodies to clostridium difficile toxins
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
AR103713A1 (es) Anticuerpos contra tau y sus usos
JP2016520595A5 (enExample)
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
JP2017521054A5 (enExample)
HRP20192038T1 (hr) Protutijela receptora anti-epidermalnog faktora rasta (egfr)
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
RU2014145536A (ru) Антитело против adamts-5, его производные и их применение
RU2016143552A (ru) Гуманизированные антитела к антигену Томсена-Фриденрайха